Literature DB >> 16353930

A new equivalence based metric for predictive check to qualify mixed-effects models.

Pravin R Jadhav1, Jogarao V S Gobburu.   

Abstract

The main objective of any modeling exercise is to provide a rationale for effective decision making during drug development. The aim of the current simulation experiment was to evaluate the properties of predictive check as a covariate model qualification technique and, more importantly, to introduce and evaluate alternative criteria to qualify models.Original concentration-time profiles (yod) were simulated using a 1-compartment model for an intravenous drug administered to 25 men and 25 women. The typical clearance for male subjects (TVCLm) was assumed to be 5-fold higher than that for female subjects (TVCLf). Fifty such trials under the same design were generated randomly. Predictive check was used as the model qualification tool to study predictive performance of true (males not equal females) and false (males = females) models in the context of maximum likelihood estimation. For each yod, 200 replications were generated to study the properties of a discrepancy variable, a statistic that depends on the model, and a test statistic, a statistic that does not depend on the model. Several qualification criteria were evaluated in assessing predictive performance, such as, predictive p-value (Pp), probability of equivalence (peqv), and probability of rejecting the null hypothesis (data = model) using the Kolmogorov-Smirnov test (pks). The Pp value was calculated using sum of squared errors as a discrepancy variable. For both of the models, the Pp values uniformly ranged between 0 and 1. The pattern of Pp values suggests that qualification of the false model is unlikely. For both of the models, the range of peqv is about 0.95 to 1.0 for concentration at 0.5 hours. However, this is not the case for the concentration at 4 hours, which is primarily dependent on the clearance. The false model (0.35 to 0.50) has poor predictive performance compared with the true model (0.65 to 0.80) using peqv. The pks suggests no difference in the distributions of replicated and original concentrations at all of the time points for both of the models. Discrepancy variables cannot aid in rejecting false models, whereas the use of a test statistic can aid in rejecting false models. However, selection of an informative test statistic is challenging. As far as the qualification criteria are considered, the equivalence-based comparison of a test statistic is more informative than a significance-based comparison. No convincing evidence exists in the literature demonstrating the added advantages of predictive check as a routine model qualification tool over the existing tools, such as diagnostic plots or mechanistic reasoning. However, when a model is to be used for designing a trial, it should at least be able to regenerate the data used to build the model. In such cases, predictive check might offer insights into potential inconsistencies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16353930      PMCID: PMC2751255          DOI: 10.1208/aapsj070353

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  7 in total

Review 1.  Pharmacokinetic/pharmacodynamic modeling in drug development.

Authors:  L B Sheiner; J L Steimer
Journal:  Annu Rev Pharmacol Toxicol       Date:  2000       Impact factor: 13.820

2.  Assessment of actual significance levels for covariate effects in NONMEM.

Authors:  U Wählby; E N Jonsson; M O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

Review 3.  Utilisation of pharmacokinetic-pharmacodynamic modelling and simulation in regulatory decision-making.

Authors:  J V Gobburu; P J Marroum
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Development of a sequential linked pharmacokinetic and pharmacodynamic simulation model for ivabradine in healthy volunteers.

Authors:  S B Duffull; L Aarons
Journal:  Eur J Pharm Sci       Date:  2000       Impact factor: 4.384

5.  A pharmacokinetic simulation model for ivabradine in healthy volunteers.

Authors:  S B Duffull; S Chabaud; P Nony; C Laveille; P Girard; L Aarons
Journal:  Eur J Pharm Sci       Date:  2000       Impact factor: 4.384

6.  Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats.

Authors:  L E Friberg; A Freijs; M Sandström; M O Karlsson
Journal:  J Pharmacol Exp Ther       Date:  2000-11       Impact factor: 4.030

7.  Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.

Authors:  Y Yano; S L Beal; L B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-04       Impact factor: 2.745

  7 in total
  16 in total

Review 1.  Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004.

Authors:  Karl Brendel; Céline Dartois; Emmanuelle Comets; Annabelle Lemenuel-Diot; Christian Laveille; Brigitte Tranchand; Pascal Girard; Céline M Laffont; France Mentré
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

2.  Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with haematological malignancies.

Authors:  Shailly Mehrotra; Mathangi Gopalakrishnan; Jogarao Gobburu; Jacqueline M Greer; Richard Piekarz; Judith E Karp; Keith Pratz; Michelle A Rudek
Journal:  Br J Clin Pharmacol       Date:  2017-03-19       Impact factor: 4.335

3.  Bayesian estimation of mycophenolate mofetil in lung transplantation, using a population pharmacokinetic model developed in kidney and lung transplant recipients.

Authors:  Brenda C M de Winter; Caroline Monchaud; Aurélie Prémaud; Christophe Pison; Romain Kessler; Martine Reynaud-Gaubert; Claire Dromer; Marc Stern; Romain Guillemain; Christiane Knoop; Marc Estenne; Pierre Marquet; Annick Rousseau
Journal:  Clin Pharmacokinet       Date:  2012-01-01       Impact factor: 6.447

4.  Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types.

Authors:  Jing Niu; Christie Scheuerell; Shailly Mehrotra; Sharon Karan; Shannon Puhalla; Brian F Kiesel; Jiuping Ji; Edward Chu; Mathangi Gopalakrishnan; Vijay Ivaturi; Jogarao Gobburu; Jan H Beumer
Journal:  J Clin Pharmacol       Date:  2017-04-07       Impact factor: 3.126

5.  Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.

Authors:  Brenda C M de Winter; Teun van Gelder; Ferdi Sombogaard; Leslie M Shaw; Reinier M van Hest; Ron A A Mathot
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-11-11       Impact factor: 2.745

6.  Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias.

Authors:  Renu Singh; Shailly Mehrotra; Mathangi Gopalakrishnan; Ivana Gojo; Judith E Karp; Jacqueline M Greer; Alice Chen; Richard Piekarz; Brian F Kiesel; Jogarao Gobburu; Michelle A Rudek; Jan H Beumer
Journal:  Cancer Chemother Pharmacol       Date:  2018-11-20       Impact factor: 3.333

7.  Pharmacokinetic modelling of the plasma protein binding of mycophenolic acid in renal transplant recipients.

Authors:  Reinier M van Hest; Teun van Gelder; Arnold G Vulto; Leslie M Shaw; Ron A A Mathot
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

8.  Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.

Authors:  Caroline Monchaud; Brenda C de Winter; Christiane Knoop; Marc Estenne; Martine Reynaud-Gaubert; Christophe Pison; Marc Stern; Romain Kessler; Romain Guillemain; Pierre Marquet; Annick Rousseau
Journal:  Clin Pharmacokinet       Date:  2012-03-01       Impact factor: 6.447

9.  Extensions to the visual predictive check to facilitate model performance evaluation.

Authors:  Teun M Post; Jan I Freijer; Bart A Ploeger; Meindert Danhof
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-01-16       Impact factor: 2.745

10.  Influence of the UGT2B7 -161C>T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients.

Authors:  Noppaket Singkham; Somchai Towanabut; Surang Lertkachatarn; Baralee Punyawudho
Journal:  Eur J Clin Pharmacol       Date:  2012-12-21       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.